Cellectis posts Q3 2026 loss, cuts headcount and pivots to in‑vivo gene editing
Cellectis SA reported a nine‑month net loss of $101.1 million for the period ended September 30, 2026, with revenue falling to about $19.9 million and R&D expenses rising to $108.8 million. The company disclosed $149 million in cash and said the balance sheet will fund operations into the second half of 2028. Management also announced a restructuring that will reduce global headcount by up to 70% as it shifts focus to in‑vivo gene‑editing programs HEAL‑101 and HEAL‑201.
Why it matters
The cash runway into H2 2028 gives the company time to advance its new HEAL programs before needing additional financing. The steep headcount reduction and higher R&D spend signal a costly transition that may affect near‑term profitability.
Key facts
- 1Nine‑month net loss of $101.1 million. tradingview.com
- 2Revenue of $19.9 million for the nine months ended September 30, 2026. tipranks.com
- 3GAAP EPS of -$1.00 for the nine‑month period. seekingalpha.com
- 4Q3 EPS of -$0.61. investing.com
- 5R&D expenses of $108.8 million for the nine‑month period. tipranks.com
- 6Cash, cash equivalents, restricted cash and fixed‑term deposits of $149 million as of September 30, 2026. tradingview.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.